Evidence map›Paper›PMID 41254794›Full record

ArticleGenome medicine2025

A comprehensive long-read sequencing system to assess DNA methylation at differentially methylated regions and imprinting-disorder-related genes.

Tatsuki Urakawa, Atsushi Hattori, Yasuko Ogiwara, Hayate Masubuchi, Mizuho Igarashi, Sayuri Nakamura, Kaori Hara-Isono, Keisuke Ishiwata, Hiroko Ogata-Kawata, Hiromi Kamura and 4 more

Abstract read
In one paragraph

Article in Genome medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Tatsuki UrakawaDepartment of Molecular Endocrinology, National Research Institute for Child Health and Development, 2-10-1 Okura, Setagaya-Ku, Tokyo, 157-8535, Japan.
Atsushi HattoriDepartment of Molecular Endocrinology, National Research Institute for Child Health and Development, 2-10-1 Okura, Setagaya-Ku, Tokyo, 157-8535, Japan.
Yasuko OgiwaraDepartment of Molecular Endocrinology, National Research Institute for Child Health and Development, 2-10-1 Okura, Setagaya-Ku, Tokyo, 157-8535, Japan.
Hayate MasubuchiDepartment of Molecular Endocrinology, National Research Institute for Child Health and Development, 2-10-1 Okura, Setagaya-Ku, Tokyo, 157-8535, Japan.
Mizuho IgarashiDepartment of Molecular Endocrinology, National Research Institute for Child Health and Development, 2-10-1 Okura, Setagaya-Ku, Tokyo, 157-8535, Japan.
Sayuri NakamuraDepartment of Molecular Endocrinology, National Research Institute for Child Health and Development, 2-10-1 Okura, Setagaya-Ku, Tokyo, 157-8535, Japan.
Kaori Hara-IsonoDepartment of Molecular Endocrinology, National Research Institute for Child Health and Development, 2-10-1 Okura, Setagaya-Ku, Tokyo, 157-8535, Japan.
Keisuke IshiwataDepartment of Maternal-Fetal Biology, National Research Institute for Child Health and Development, 2-10-1 Okura, Setagaya-Ku, Tokyo, 157-8535, Japan.
Hiroko Ogata-KawataDepartment of Maternal-Fetal Biology, National Research Institute for Child Health and Development, 2-10-1 Okura, Setagaya-Ku, Tokyo, 157-8535, Japan.
Hiromi KamuraDepartment of Maternal-Fetal Biology, National Research Institute for Child Health and Development, 2-10-1 Okura, Setagaya-Ku, Tokyo, 157-8535, Japan.
Yoko KurokiDivision of Diversity Research, National Research Institute for Child Health and Development, 2-10-1 Okura, Setagaya-Ku, Tokyo, 157-8535, Japan.
Kazuhiko NakabayashiDepartment of Maternal-Fetal Biology, National Research Institute for Child Health and Development, 2-10-1 Okura, Setagaya-Ku, Tokyo, 157-8535, Japan.
Maki FukamiDepartment of Molecular Endocrinology, National Research Institute for Child Health and Development, 2-10-1 Okura, Setagaya-Ku, Tokyo, 157-8535, Japan.
Masayo KagamiDepartment of Molecular Endocrinology, National Research Institute for Child Health and Development, 2-10-1 Okura, Setagaya-Ku, Tokyo, 157-8535, Japan. kagami-ms@ncchd.go.jp.

Funding

Japan Agency for Medical Research and Development JP25ek0109805Japan Society for the Promotion of Science 22K07858 [C]National Center for Child Health and Development 2022B-5
6 · The paper itself

Abstract

backgroundImprinted genes are expressed in a parental-origin-specific manner. The imprinted regions including imprinted genes have differentially methylated regions (DMRs) with different 5-methylcytosine (5mC) patterns for CpGs on each parental allele, and DMRs function as imprinting control centers. Aberrant expression of the imprinted genes caused by structural variants involving DMRs, single-nucleotide variants in imprinted genes, uniparental disomy, and epimutation lead to imprinting disorders (IDs). Nanopore-based targeted long-read sequencing (T-LRS) can obtain sequence reads 10-100 kb long together with information on DNA methylation in each CpG and is cost-effective compared to whole-genome LRS. T-LRS is a valuable tool for efficient genetic testing for IDs and has great potential to elucidate the regulatory mechanisms in the imprinted regions. However, there is no T-LRS system targeting all ID-related regions.

methodsWe conducted T-LRS targeting 78 DMRs and 22 genes in peripheral blood leukocytes from six healthy controls and set the normal range of methylation index (MI) for each CpG within the DMRs. To clarify the properties of DMRs, we compared MIs in CpGs within DMRs between haplotypes in 78 DMRs. To evaluate the usefulness of T-LRS, we conducted T-LRS on two previously reported patients with multi-locus imprinting disturbance (MLID) having pathogenic variants in MLID-causative genes and compared the MIs in CpGs within DMRs with those measured by array-based methylation analysis.

resultsThe median number of reads with 5mC and unmethylated cytosine in all DMRs in the six controls was over 40. We defined the normal range of MI for all CpGs in each allele and the total, and classified 78 DMRs into three categories, namely, 33 Complete-DMRs, 25 Partial-DMRs, and 20 Non-DMRs, based on the average of six controls for the median of differences of MIs in CpGs between haplotypes. We confirmed by T-LRS pathogenic variants in MLID-causative genes in patients with MLID. The patients' methylation defect patterns in T-LRS were similar to those in array-based methylation analysis, although T-LRS showed additional aberrantly methylated DMRs.

conclusionsWe established a T-LRS system targeting all ID-related regions, defined standard MI ranges in CpGs on each parental allele, and demonstrated the usefulness of T-LRS.

Indexed as

DNA MethylationGenomic ImprintingSequence Analysis, DNACpG IslandsFemaleHigh-Throughput Nucleotide SequencingHumansMaleAdaptive samplingDifferentially methylated regionImprinting disordersLong-read sequencingMethylation

Identifiers

PMID41254794
PMCPMC12628973

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.